CN110655577A - APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 - Google Patents

APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 Download PDF

Info

Publication number
CN110655577A
CN110655577A CN201810606914.0A CN201810606914A CN110655577A CN 110655577 A CN110655577 A CN 110655577A CN 201810606914 A CN201810606914 A CN 201810606914A CN 110655577 A CN110655577 A CN 110655577A
Authority
CN
China
Prior art keywords
seq
antibody
amino acid
elabela
fusion protein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810606914.0A
Other languages
English (en)
Chinese (zh)
Inventor
张�成
孙蕾
王荣柱
药晨江
汪笑峰
章华
景书谦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Gmax Biopharm LLC
Original Assignee
Gmax Biopharm LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Gmax Biopharm LLC filed Critical Gmax Biopharm LLC
Priority to CN202411770887.2A priority Critical patent/CN119613548A/zh
Priority to CN201810606914.0A priority patent/CN110655577A/zh
Priority to US17/251,663 priority patent/US12221488B2/en
Priority to JP2020569130A priority patent/JP7674837B2/ja
Priority to KR1020217000999A priority patent/KR102880176B1/ko
Priority to CA3103585A priority patent/CA3103585A1/en
Priority to EP19819592.7A priority patent/EP3808847A4/en
Priority to AU2019284320A priority patent/AU2019284320B2/en
Priority to PCT/CN2019/091090 priority patent/WO2019238093A1/zh
Publication of CN110655577A publication Critical patent/CN110655577A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/72—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • C07K14/723—G protein coupled receptor, e.g. TSHR-thyrotropin-receptor, LH/hCG receptor, FSH receptor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
CN201810606914.0A 2018-06-13 2018-06-13 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用 Pending CN110655577A (zh)

Priority Applications (9)

Application Number Priority Date Filing Date Title
CN202411770887.2A CN119613548A (zh) 2018-06-13 2018-06-13 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
CN201810606914.0A CN110655577A (zh) 2018-06-13 2018-06-13 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
US17/251,663 US12221488B2 (en) 2018-06-13 2019-06-13 APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereofus01
JP2020569130A JP7674837B2 (ja) 2018-06-13 2019-06-13 Ａｐｊ抗体及びｅｌａｂｅｌａとのその融合タンパク質並びにその医薬組成物及び用途
KR1020217000999A KR102880176B1 (ko) 2018-06-13 2019-06-13 Apj 항체 및 이와 엘라벨라의 융합 단백질, 및 그의 약학 조성물 및 적용
CA3103585A CA3103585A1 (en) 2018-06-13 2019-06-13 Apj antibody and its fusion protein with elabela, and pharmaceutical composition and application thereof
EP19819592.7A EP3808847A4 (en) 2018-06-13 2019-06-13 Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof
AU2019284320A AU2019284320B2 (en) 2018-06-13 2019-06-13 APJ antibody, fusion protein thereof with Elabela, and pharmaceutical compositions and use thereof
PCT/CN2019/091090 WO2019238093A1 (zh) 2018-06-13 2019-06-13 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810606914.0A CN110655577A (zh) 2018-06-13 2018-06-13 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202411770887.2A Division CN119613548A (zh) 2018-06-13 2018-06-13 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用

Publications (1)

Publication Number Publication Date
CN110655577A true CN110655577A (zh) 2020-01-07

Family

ID=68842717

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810606914.0A Pending CN110655577A (zh) 2018-06-13 2018-06-13 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用
CN202411770887.2A Pending CN119613548A (zh) 2018-06-13 2018-06-13 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN202411770887.2A Pending CN119613548A (zh) 2018-06-13 2018-06-13 APJ抗体及其与Elabela的融合蛋白质，以及其药物组合物和应用

Country Status (8)

Country Link
US (1) US12221488B2 (https=)
EP (1) EP3808847A4 (https=)
JP (1) JP7674837B2 (https=)
KR (1) KR102880176B1 (https=)
CN (2) CN110655577A (https=)
AU (1) AU2019284320B2 (https=)
CA (1) CA3103585A1 (https=)
WO (1) WO2019238093A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112210001A (zh) * 2020-10-25 2021-01-12 兰州大学 多肽片段ela13及其用途

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10138569A1 (de) * 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
US20140170134A1 (en) * 2011-08-15 2014-06-19 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
US20140328850A1 (en) * 2011-07-18 2014-11-06 Shu-Chen Lu Apelin antigen-binding proteins and uses thereof
CN104371019A (zh) * 2013-08-13 2015-02-25 杭州鸿运华宁生物医药工程有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN105026423A (zh) * 2013-03-14 2015-11-04 瑞泽恩制药公司 爱帕琳融合蛋白和其用途
CN105916881A (zh) * 2013-11-20 2016-08-31 瑞泽恩制药公司 Aplnr调节剂及其用途
CN106659774A (zh) * 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
US20170146518A1 (en) * 2014-03-20 2017-05-25 Centre National De La Recherche Scientifique (Cnrs) Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer
US20170224779A1 (en) * 2014-10-13 2017-08-10 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
CN107646039A (zh) * 2015-04-02 2018-01-30 埃博灵克斯股份有限公司 具有有效抗hiv活性的双特异性cxcr4‑cd4多肽

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4751180A (en) 1985-03-28 1988-06-14 Chiron Corporation Expression using fused genes providing for protein product
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4935233A (en) 1985-12-02 1990-06-19 G. D. Searle And Company Covalently linked polypeptide cell modulators
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5011912A (en) 1986-12-19 1991-04-30 Immunex Corporation Hybridoma and monoclonal antibody for use in an immunoaffinity purification system
US5262522A (en) 1991-11-22 1993-11-16 Immunex Corporation Receptor for oncostatin M and leukemia inhibitory factor
PT672141E (pt) 1992-10-23 2003-09-30 Immunex Corp Metodos de preparacao de proteinas oligomericas soluveis
US5457035A (en) 1993-07-23 1995-10-10 Immunex Corporation Cytokine which is a ligand for OX40
US6133426A (en) 1997-02-21 2000-10-17 Genentech, Inc. Humanized anti-IL-8 monoclonal antibodies
EP1958962A3 (en) 1997-06-12 2013-05-01 Novartis International Pharmaceutical Ltd. Artificial antibody polypeptides
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
KR20010033601A (ko) * 1997-12-24 2001-04-25 다케다 야쿠힌 고교 가부시키가이샤 폴리펩티드, 그의 제법 및 용도
US6210924B1 (en) 1998-08-11 2001-04-03 Amgen Inc. Overexpressing cyclin D 1 in a eukaryotic cell line
GB9928787D0 (en) 1999-12-03 2000-02-02 Medical Res Council Direct screening method
GB0025144D0 (en) 2000-10-13 2000-11-29 Medical Res Council Concatenated nucleic acid sequences
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US20040202995A1 (en) 2003-04-09 2004-10-14 Domantis Nucleic acids, proteins, and screening methods
WO2005106493A1 (en) 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled apelin receptor (apj)
WO2006023893A2 (en) * 2004-08-23 2006-03-02 Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for modulating angiogenesis and apoptosis with apelin compositions
WO2012102363A1 (ja) * 2011-01-28 2012-08-02 国立大学法人大阪大学 薬物送達システムおよびその利用
EP3672987B1 (en) * 2017-08-24 2025-04-16 Phanes Therapeutics, Inc. Anti-apelin antibodies and uses thereof

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10138569A1 (de) * 2001-08-06 2003-04-30 Bayer Ag Regulation des APJ-Rezeptors
US20140328850A1 (en) * 2011-07-18 2014-11-06 Shu-Chen Lu Apelin antigen-binding proteins and uses thereof
US20140170134A1 (en) * 2011-08-15 2014-06-19 The University Of Chicago Compositions and methods related to antibodies to staphylococcal protein a
CN105026423A (zh) * 2013-03-14 2015-11-04 瑞泽恩制药公司 爱帕琳融合蛋白和其用途
CN104371019A (zh) * 2013-08-13 2015-02-25 杭州鸿运华宁生物医药工程有限公司 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质
CN105916881A (zh) * 2013-11-20 2016-08-31 瑞泽恩制药公司 Aplnr调节剂及其用途
US20170146518A1 (en) * 2014-03-20 2017-05-25 Centre National De La Recherche Scientifique (Cnrs) Use of compounds inhibiting apelin / apj / gp130 signaling for treating cancer
CN106659774A (zh) * 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
US20170224779A1 (en) * 2014-10-13 2017-08-10 University Of Maryland, Baltimore Methods for treating cardiovascular dysfunction and improving fluid homeostasis with a peptide hormone
CN107646039A (zh) * 2015-04-02 2018-01-30 埃博灵克斯股份有限公司 具有有效抗hiv活性的双特异性cxcr4‑cd4多肽

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRIDGET A. PUFFER等: "Expression and coreceptor function of APJ for primate immunodeficiency viruses", 《VIROLOGY》, vol. 276, no. 02, pages 435 - 444, XP004435851, DOI: 10.1006/viro.2000.0557 *
GENBANK: "AAO73022.1: anti-meningococcal polysaccharide group C monoclonal antibody 1922.2 immunoglobulin light chain, partial [Mus musculus]", 《GENBANK》 *
GENBANK: "AGN91363.1: immunoglobulin heavy chain variable region, partial [Mus musculus]", 《GENBANK》 *
ZHI WANG等: "Elabela-Apelin Receptor Signaling Pathway is Functional in Mammalian Systems", 《SCIENTIFIC REPORTS》, no. 05, pages 8170 *
欧阳芝玉、田国平: "Apelin/APJ系统在心力衰竭中的研究进展", 《社区医学杂志》, vol. 13, no. 23, pages 78 - 80 *
靶向APJ受体的药物再评价与可比司它抑制APELIN亚型诱导的血小板聚集: "靶向APJ受体的药物再评价与可比司它抑制Apelin亚型诱导的血小板聚集", 《中国优秀硕士学位论文全文数据库》, no. 2018 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112210001A (zh) * 2020-10-25 2021-01-12 兰州大学 多肽片段ela13及其用途

Also Published As

Publication number Publication date
KR102880176B1 (ko) 2025-11-04
WO2019238093A1 (zh) 2019-12-19
US20210163614A1 (en) 2021-06-03
KR20210019535A (ko) 2021-02-22
CA3103585A1 (en) 2019-12-19
JP2021526833A (ja) 2021-10-11
JP7674837B2 (ja) 2025-05-12
EP3808847A1 (en) 2021-04-21
AU2019284320B2 (en) 2025-12-18
EP3808847A4 (en) 2022-08-31
AU2019284320A1 (en) 2021-02-04
US12221488B2 (en) 2025-02-11
CN119613548A (zh) 2025-03-14

Similar Documents

Publication Publication Date Title
CN105669863B (zh) 一种能与人内皮素受体特异性结合的抗体及其应用
TWI889705B (zh) Gipr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用
TWI832847B (zh) Gipr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用
EP4585617A1 (en) Gipr antibody, fusion protein thereof with fgf21, pharmaceutical composition thereof, and use thereof
WO2021008519A1 (zh) ETA抗体与TGF-βTrap的融合蛋白质，以及其药物组合物和应用
TWI842699B (zh) Gcgr抗體及其與glp-1的融合蛋白質，以及其藥物組合物和應用
JP7674837B2 (ja) Ａｐｊ抗体及びｅｌａｂｅｌａとのその融合タンパク質並びにその医薬組成物及び用途
WO2020248967A1 (zh) Eta抗体与bnp的融合蛋白质，以及其药物组合物和应用
US20260125484A1 (en) Antibody capable of specifically binding to human endothelin receptor, and use thereof in treatment of diabetic nephropathy and chronic nephropathy
EP4317187A1 (en) Antibody capable of specifically binding to human endothelin receptor, and use thereof in treatment of diabetic nephropathy and chronic nephropathy
HK40020380A (en) Apj antibody, fusion protein thereof with elabela, and pharmaceutical compositions and use thereof
HK40016223B (en) Gcgr antibody and glp-1 fusion protein thereof, and pharmaceutical composition and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40020380

Country of ref document: HK

SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination